KPIs & Operating Metrics(New)
Growth Metrics

Astrazeneca (AZN) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Astrazeneca (AZN) over the last 17 years, with Q4 2025 value amounting to $15.2 billion.

  • Astrazeneca's Receivables - Net rose 1699.81% to $15.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $15.2 billion, marking a year-over-year increase of 1699.81%. This contributed to the annual value of $15.2 billion for FY2025, which is 1699.81% up from last year.
  • Latest data reveals that Astrazeneca reported Receivables - Net of $15.2 billion as of Q4 2025, which was up 1699.81% from $14.3 billion recorded in Q3 2025.
  • Astrazeneca's 5-year Receivables - Net high stood at $15.2 billion for Q4 2025, and its period low was $6.3 billion during Q1 2021.
  • For the 5-year period, Astrazeneca's Receivables - Net averaged around $10.8 billion, with its median value being $11.1 billion (2024).
  • Its Receivables - Net has fluctuated over the past 5 years, first soared by 7904.82% in 2021, then crashed by 40.57% in 2024.
  • Astrazeneca's Receivables - Net (Quarter) stood at $9.6 billion in 2021, then grew by 9.09% to $10.5 billion in 2022, then rose by 15.26% to $12.1 billion in 2023, then increased by 6.98% to $13.0 billion in 2024, then grew by 17.0% to $15.2 billion in 2025.
  • Its Receivables - Net stands at $15.2 billion for Q4 2025, versus $14.3 billion for Q3 2025 and $14.2 billion for Q2 2025.